Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, Phase I/II, single arm trial to assess the safety and efficacy
of the combination of oral rucaparib plus intravenous pembrolizumab as maintenance therapy in
patients with stage IV non-squamous non-small cell lung cancer (NSCLC) without progressive
disease (PD), as confirmed on CT scans, after induction therapy with
carboplatin/pemetrexed/pembrolizumab (CPP) triplet therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center